The University of California, Los Angeles/Jennifer Jones Simon Foundation symposium on prostate cancer and epithelial cell biology: bringing together basic scientists and clinicians in the fight against advanced prostate cancer.
Prostate cancer is the most common solid tumor in American men and is the second most common cause of cancer deaths. Although surgery and radiation therapy are effective for the treatment of organ-confined cancer, there is no effective treatment that is currently available for patients who have metastatic disease. Antiandrogen therapy is only palliative, and chemotherapy has largely been ineffective. However, recent advances in the understanding of the molecular biology of prostate cancer have lead to the development of new treatment strategies for metastatic cancer, including gene-based therapies, immunotherapies, and antiangiogenesis-based therapy. In association with the Jonsson Comprehensive Cancer Center and the University of California, Los Angeles Department of Urology, the Jennifer Jones Simon Foundation assembled 30 of the world's experts in prostate cancer research to review the most recent advances in the study of prostate cancer, with the hope that the resulting discussions would facilitate the rapid translation of new discoveries from the laboratory bench to the clinic.
Naitoh
J
J
Department of Urology, UCLA School of Medicine, Los Angeles, California 90095-1738, USA.
Witte
O
O
Belldegrun
A
A
D000970:Antineoplastic Agents / Q000627:therapeutic use; D017209:Apoptosis; D015820:Cadherins / Q000378:metabolism; D004195:Disease Models, Animal; D004730:Endothelium, Vascular / Q000737:chemistry; D015316:Genetic Therapy; D006801:Humans; D007167:Immunotherapy; D015141:Los Angeles; D008297:Male; D017720:Molecular Epidemiology; D011471:Prostatic Neoplasms / Q000235:genetics / Q000473:pathology / Q000628:therapy; D012106:Research
D000970:Antineoplastic Agents; D015820:Cadherins